Abbott and Brazil Reach Agreement. No Patent Will Be Broken.

Abbott announced today that it achieved its goals in negotiating an agreement with the government of Brazil regarding Kaletra (lopinavir/ritonavir), the leading protease inhibitor used as an AIDS treatment. 

According to the American laboratory, the agreement accomplishes Abbott’s objectives of helping Brazil expand patient access to Kaletra while preserving the company’s intellectual property rights, which Abbott was not willing to negotiate.


The agreement does not specify a per-capsule price, and will not be at the low price quoted for local and generic manufacturers.  The price of Kaletra will be dependent on the number of patients treated.


Abbott agreed to provide assistance to Brazil to enable local manufacture of Kaletra for HIV/AIDS patients in Brazil once the patent expires in 2015. Terms of this portion of the agreement are under discussion.


Abbott said in a statement: “It is strong intellectual property protection that has enabled the discovery and development of the many HIV treatments available for patients today, and also ensures future advances to address a virus that continues to mutate and elude a cure. 


“Abbott is committed to protecting its intellectual property so that innovation flourishes for the benefit of patients around the world.”


Safety Information


Kaletra is always used in combination with other anti-HIV medicines to treat people with human immunodeficiency virus (HIV) infection.


Kaletra should not be taken by patients who have had an allergic reaction to Kaletra or any of its ingredients, including lopinavir or ritonavir.


Taking certain medications with Kaletra could create the potential for serious side effects that could be life threatening. 


Kaletra should not be taken with astemizole, cisapride, dihydroergotamine, ergonovine, ergotamine, methylergonovine, midazolam, pimozide, terfenadine or triazolam.


In addition, Kaletra should not be taken with fluticasone propionate, rifampin, simvastatin, or products containing St. John’s Wort (Hypericum perforatum). 


Particular caution should be used when taking Kaletra with sildenafil, tadalafil, or vardenafil.  Pancreatitis and liver problems, which can be fatal, have been reported.


Patients should tell their doctor if they have had liver disease such as hepatitis.  In patients taking protease inhibitors, increased bleeding (in patients with hemophilia) and diabetes/high blood sugar have occurred.


Changes in body fat have been seen in some patients receiving antiretroviral therapy.  Some patients receiving Kaletra have had large increases in triglycerides and cholesterol.  Varying degrees of cross-resistance among protease inhibitors have been observed.


In Kaletra clinical trials, the most commonly reported side effects of moderate-to-severe intensity were abdominal pain, abnormal bowel movements, diarrhea, feeling weak or tired, headache, nausea and vomiting. 


Children taking Kaletra may sometimes get a skin rash.  This is not a complete list of reported side effects.  Kaletra oral solution contains alcohol.


Kaletra does not cure HIV infection or AIDS and does not reduce the risk of passing HIV to others.


Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs more than 60,000 people and markets its products in more than 130 countries.


Abbott – www.abbott.com
Kaletra – www.kaletra.com

Tags:

You May Also Like

Brazil Accused of Stealing Nuclear Technology

Brazilian authorities argue that it is all rumor and innuendo without any basis in ...

US Delegation for Inauguration of Brazil’s New President to Be Headed by Hillary Clinton

Hillary Clinton, the US secretary of State will head the United States delegation to ...

Brazil Has Best Science Base Outside G8, says UK

A British spokesman for the UK Trade & Investment (UKTI) said that Brazil has ...

Best-seller Books, Plays and Movies

By Brazzil Magazine PLAYS RIO Os Ratos do Ano 2030 (The Mice from the ...

Brazil’s Corruption Scandal Has Spared Lula for Now, But Government Is Paralyzed

The corruption scandal engulfing Brazil is beginning to have effects on the economy and ...

Dispute Between Guaranis and Multinational Land 15 Brazilian Indians in Jail

Fifteen Tupinikim and Guarani indigenous people and seven non-indigenous people were arrested on August ...

Brazil Gets an Arab Hand on Goat Raising

Brazil is testing a kind of food that is originally from the Arab countries ...

Lula Tours 5 Latin American Countries on an Ethanol Boosting Mission

Brazilian President, Luiz Inácio Lula da Silva, began a six-day, five-nation tour Sunday, August ...

Brazil’s Primary Surplus to Drop Below 4% of GDP

Brazil posted a 4.32% of GDP primary surplus in 2006 compared to 4.83% in ...

Brazil Drafts National Health System to Help Fight Child Labor

Starting today, the fight against child labor will count on the assistance of workers ...